Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1966 1
1967 1
1969 2
1970 1
1971 1
1972 5
1973 3
1974 3
1975 5
1976 6
1977 3
1978 5
1979 6
1980 3
1981 3
1982 9
1983 15
1984 13
1985 5
1986 16
1987 16
1988 19
1989 23
1990 27
1991 22
1992 32
1993 18
1994 28
1995 36
1996 56
1997 48
1998 52
1999 48
2000 70
2001 66
2002 83
2003 126
2004 153
2005 185
2006 210
2007 233
2008 296
2009 357
2010 405
2011 427
2012 460
2013 532
2014 600
2015 699
2016 710
2017 754
2018 903
2019 1075
2020 1298
2021 1472
2022 1790
2023 1834
2024 793

Text availability

Article attribute

Article type

Publication date

Search Results

14,316 results

Results by year

Filters applied: . Clear all
Page 1
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: yang r. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity.
Long X, Zhang S, Wang Y, Chen J, Lu Y, Hou H, Lin B, Li X, Shen C, Yang R, Zhu H, Cui R, Cao D, Chen G, Wang D, Chen Y, Zhai S, Zeng Z, Wu S, Lou M, Chen J, Zou J, Zheng M, Qin J, Wang X. Long X, et al. Among authors: yang r. Nat Immunol. 2024 Mar;25(3):525-536. doi: 10.1038/s41590-024-01746-8. Epub 2024 Feb 14. Nat Immunol. 2024. PMID: 38356061
Prothrombin Time.
Yang R, Zubair M, Moosavi L. Yang R, et al. 2024 Jan 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2024 Jan 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31334989 Free Books & Documents.
Anti-Aging Drugs and the Related Signal Pathways.
Du N, Yang R, Jiang S, Niu Z, Zhou W, Liu C, Gao L, Sun Q. Du N, et al. Among authors: yang r. Biomedicines. 2024 Jan 8;12(1):127. doi: 10.3390/biomedicines12010127. Biomedicines. 2024. PMID: 38255232 Free PMC article. Review.
Immunotherapy for Ovarian Cancer: Disappointing or Promising?
Deng M, Tang F, Chang X, Liu P, Ji X, Hao M, Wang Y, Yang R, Ma Q, Zhang Y, Miao J. Deng M, et al. Among authors: yang r. Mol Pharm. 2024 Feb 5;21(2):454-466. doi: 10.1021/acs.molpharmaceut.3c00986. Epub 2024 Jan 17. Mol Pharm. 2024. PMID: 38232985 Review.
14,316 results
You have reached the last available page of results. Please see the User Guide for more information.